The Global Training Hub for Biomanufacturing (GTH-B) invites participation in the Introductory Course for Biologics Development and Manufacturing in June 2024. Established by the Ministry of Health and Welfare Korea (MoHWK) with WHO support, this program aims to enhance biomanufacturing capacities in Low and Middle-Income Countries (LMICs). Coordinated by the International Vaccine Institute (IVI), GTH-B has trained over 500 individuals from more than 40 LMICs since 2022.
The 2024 course will focus on pre-clinical and clinical trials, biological manufacturing processes, quality control, and regulatory affairs, hosting 130 trainees from more than 20 LMICs. This initiative seeks to bridge the gap in vaccine and biologics access by building local manufacturing capabilities.
Andre Ditya Maulana Lubis, representing EHI, complements this effort by focusing on pre-clinical and clinical objectives. EHI collaborates with Biopharma and the Mahidol-Oxford Research Unit in Thailand, working under WHO guidelines. This collaboration forms the core group for vaccine development against infectious diseases in the country, including malaria, and will drive national capacity building for vaccines. Our efforts aim to strengthen Indonesia’s biomanufacturing capabilities and contribute to global health security.
Related news and media coverage:
